Device Trial Radar · NCT05639309
Liver Regional Oxygen Saturation in Preterm Patent Ductus Arteriosus
Last checked: Nov 20, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jan 13, 2023
Primary completion
Mar 31, 2025
Study completion Mar 31, 2025
Sponsor
- Lead sponsor
- Seoul St. Mary's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Research Foundation of Korea
- First posted
- Dec 6, 2022
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, up to 4 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the usefulness of liver perfusion and oxygenation status using regional oxygen saturation (RSO2) values obtained via near-infrared spectroscopy in assessing the hemodynamical significance of patent ductus arteriosus in preterm infants.
Conditions
- Patent Ductus Arteriosus
- Circulation
- Newborn Morbidity
- Premature Birth
Interventions
near-infrared spectroscopy based cerebral/somatic oximeter system (INVOS™ system manufactured by Medtronics)Device
regional oxygen saturation measurement
Primary outcomes
What the sponsor says the trial is designed to measure.
- Day 2 liver regional oxygen saturationTime frame: 48 to 72 hours of birth
2 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul St. Mary's Hospital
Seoul, Seocho-Gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.